Wuhan YZY Biopharma Co Ltd
Company Profile
Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).
Contact
No. 666 Gaoxin Road
Building C2-1, Guanggu Biocity
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHNT: +86 2782668988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,341.00 | 53.10 | 0.64% |
| CAC 40 | 7,608.07 | 52.20 | 0.69% |
| DAX 40 | 22,574.87 | 149.04 | 0.66% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,475.82 | 12.36 | 0.15% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 36,045.38 | 205.39 | 0.57% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,126.20 | 55.60 | 0.69% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |